Sage Therapeutics Stock News

Biogen recently announced a $1.5 billion collaboration agreement with Sage Therapeutics. Despite an earlier failed trial, Zuranolone is a promising therapy for depression.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives

The shares of Sage Therapeutics Inc (NASDAQ:SAGE) are down 1.8% at $72.78 at last check, after Raymond James downgraded the stock to "Market Perform" from "Outperform," following its recent $1.5 billi

Biogen Inc. and Sage Therapeutics Inc. said Monday they have agreed to jointly develop therapies to treat depression and movement disorders in a deal in which Biogen will give Sage $1.525 billion in c

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement

Sage Therapeutics' (SAGE) Management on Q3 2020 Results - Earnings Call Transcript

Shares of Sage Therapeutics (NASDAQ: SAGE) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share increased 41.67% year over year to ($2.03), which beat the estima

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives

Sage Therapeutics has shown impressive results on the charts YTD, where shareholders have enjoyed +169% gains since the selloff. The stock has bounced away from support nicely 5 times since then, with